To do business needs capital. There are many ways to acquire the capital. Without capital there is no chance to expand the company businesses. There is a number of plans for Fast to venture in new businesses.

The company without enough cash in its account, can generated the capital needed by exercising a debt/loan financing. The company also can generated the capital to do new investments via the issuance of new shares by exercising PP or RI. It’s not involved any major debt/loan financing facilities and it’s a ZERO RISKS FINANCING exercises .

By doing so, the company can minimize the risks of higher debt burden by the company in the future. The financing facility via issuance of new shares also could minimize the cost of financing for the company.

If the new businesses are truly have good potential to improve the revenue and profitability of the company, I think the big NOSH issues should be no issues at all.

Furthermore, my logic is, the company with plans to do something for betterment of the company is better than the company without any plans. Yes, every investment has many risks but it also maybe has many opportunities.

@dchin.

Why so afraid of a company with 1 billion or more shares?

Look at Hong Seng, it NOSH is 2.457 bil but its price is @RM1.70. For MY E.G, its NOSH will be 8 bil + after Bonus issue. Currently, MY E.G NOSH is 3.772 bil but its share price is @RM1.96.

Therefore, the most important aspects to be look at Fast should be the company's ability to improve its businesses, profitability and FA conditions.

If the company has a bright prospects because of exercising plans of businesses by uplifting the NOSH via right issue of shares or PP, I think it's a good move done by the company.

@whistlebower99.

I WANT TO TEST MY SIMPLE THEORY OF THE RI EXERCISES ON KANGER:

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.


And:


I'm keep waiting for a good announcement from Kanger, BEFORE THE EX-DATE FOR THE RIGHT OR AT LEAST BEFORE THE ACCEPTANCE AND PAYMENT DATE FOR THE RIGHT ISSUE.

If there is any, its can be a catalyst for the price to be pushed up. The current price later should be push up to the higher level to make sure that the RI will be a success.

Take a note that the issue price for the RI share is @ 6 sen per share.>>>>>>>>>>>>>>>>>


AFTER ALL. TAYOR

wistlebower99.

I'm here safe and sound. Thank God.

@18KHarmoni. Pelabur Solution pun sudah lama menunggu Solution dapat realisasikan plan jadi pengedar vaksin Sinovac. Sudah lama dah rancangan tu dibuat. Hari ini baru sampai, confirmed.

Kalau ada rezeki tu adalah nanti. Kalau langsung tak ada, memang con lah Kanger. He He

SORRY. Reposting idea only. JUST FOR NEWBIES...
He He.

Waiting for a good announcement from Kanger, BEFORE THE EX-DATE FOR THE RIGHT OR AT LEAST BEFORE THE ACCEPTANCE AND PAYMENT DATE FOR THE RIGHT ISSUE.

If there is any, its can be a catalyst for the price to be pushed up. The current price later should be push up to the higher level to make sure that the RI will be a success.

Take a note that the issue price for the RI share is @ 6 sen per share.>>>>>>>>>>>>>>>>>

United Arab Emirates
The UAE began production of Hayat-Vax, a locally manufactured version of China’s Sinopharm vaccine, in March 2021. Current plans include the production of 2 million doses per month, a majority of which will be exported to low-income countries, particularly Africa and the Middle East, under the WHO’s COVAX scheme.[47][48] By being produced in the UAE, Hayat-Vax is believed to be able to “resolve many of the issues plaguing public acceptance of other vaccines” in Middle Eastern countries.[49]

Solution Biologics is the product registration holder for CanSino in Malaysia.
-------------

If Solution Biologics can own the product registration holder for Covid-19 vaccine, Kanger also can be approved with Hayat-Vax vaccine product registration holder.

------------------

"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.

Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.

Hope the time will come. Sooner or later.

18KHarmoni Kerja operator and promoter is keeping update the RECYLCLE information
-------------
Oh yeah.. Yes, It's a CON counter. It's a CONSTRUCTION RELATED counter. He He

@whistlebower99.

Kanger is still in progressing state in its current businesses, which are a bamboo flooring and related products, and Kanger also in its plan to venture in other business activities such as been involved in the construction services, in a process to acquire property for investment and in a final process to acquire a company which involved in a construction material trading.

All sort of the new investments in the new businesses has expanded via internally generated funds or by the issuance of new shares in Kanger. Its not involved any major debt financing facilities and it’s a ZERO RISKS FINANCING exercises . Therefore the company can minimize the risks of higher debt burden by the company in the future. The financing facility via issuance of new shares also could minimize the cost of financing for the company.

If the new businesses are truly have good potential to improve the revenue and profitability of the company

@awesome. A spam counter attacked by a spam.
By the way I held some BPuri shares and have a plan to hold it.
I'm sorry.

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
------------

Ya lah betullah tu. Dengar berita dari orang bermuka-muka banyak ni lebih baik JANGAN PERCAYA SAHAJA. MUDAH KAN? He He.

Saya berhenti dahulu lah komen kat sini. Nanti kalau ada berita saya update.

BAGI PELUANG OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 MEROYAN SEPUAS-PUASNYA....

Nanti tolong buat lagilah 10 ID baru ye...

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------

Apasal teruk MEROYAN hari ini tu....

Terjerat banyak dekat kaunter ASB ke ???
Sabar ajalah....

@whistlebower99.


Bolehlah awak kaji sedikit siapa substantial holder yang awak maksudkan. Adakah dia sebenarnya genuine shareholder yang beli saham untuk pelaburan atau tidak?

Boleh terangkan sedikit kepada kami semua.


TOLONG KOMEN BERITA YANG POSITIF INI:

BOD sedang meningkatkan peratus pegangan sahamnya dalam syarikat. Setahu saya, ianya amat baik untuk syarikat.

BOD Hj Mazru sudah tingkatkan kepentingan sahamnya ke 14.074%. Memiliki saham sebanyak 557,400,000 unit. Hari ini saja dah tambah share sebanyak 143,000,000 unit saham.
Dia belum pernah jual setakat hari ini.

Sumber: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3183922

FRIENDS:
Kita mungkin boleh perhatikan kebanyakan syarikat yang buat consolidation ialah apabila syarikat mengalami kerugian terkumpul yang banyak selain daripada NOSH yang besar. Banyak syarikat yang mempunyai masalah kerugian terkumpul yang besar akan buat capital reduction bersama-sama dengan proses consolidation.

Dan biasanya, syarikat yang mempunyai BOD yang hanya memiliki peratus saham yang sedikit biasanya suka buat consolidation. Ini kerana kesan negatif consolidation banyak ditanggung oleh pelabur runcit berbanding pemegang saham insider.

NOSH yang besar bukan jadi sebab mewajibkan sesebuah syarikat membuat consolidation. Kecualilah:

1. Keadaan kewangan syarikat amat memerlukan consolidation dibuat, contohnya dalam keadaan kerugian terkumpul yang banyak dalam kunci kira-kira.

2. Atau ada UDANG DISEBALIK BATU dalam kalangan pengurusan sesebuah syarikat tertentu.

JIKA NOSH besar, keadaan kewangan okay, harga saham pun OKAY, syarikat tersebut rasanya tak perlu buat consolidation. LIHAT SAJA CONTOH MY E.G. Bukannya nak buat consolidation tetapi menambahkan lagi jumlah NOSH syarikat sampai 8 bilion unit melalui Bonus Issue.

KAJIAN KES MELIBATKAN NEXGRAM:
1. Nexgram telah melaksanakan capital reduction dan ianya akan secara rasmi diambil kira ke dalam akaun bagi 4QR 2021. Semua kerugian terkumpul akan di offsett dengan perolehan capital reduction dan kunci kira-kira akan mula menunjukkan baki retained earning bermula dalam akaun 4QR 2021.
2. Berlaku perubahan struktur pemegangan saham dalam Nexgram. Pemegang saham dari kalangan BOD telah bertambah, contohnya Hj Mazru telah pegang kepentingan 10.855% dan ianya mungkin akan ditingkatkan sehingga 25% kepentingan saham.

Kesimpulan: Atas dasar tiada lagi masalah kerugian terkumpul yang besar dalam syarikat dan kepentingan saham yang dipegang dari kalangan insider syarikat adalah besar, maka saya rasa kemungkinan syarikat untuk membuat consolidation adalah lebih rendah.

@whistlebower99.

For your information the NOSH of Hong Seng also quite high. It's at 2,457 Million. MY E.G also will have a NOSH of 8 bil + after Bonus Share.

Please do not compare certain company with different management and different problem with ALMOST ALL the companies in FINTECH group...

Please don't ever be A BLIND PARROT spammer anymore. I BEG YOU.

By the way, I also hope you can put Hong Seng and MY E.G in your list of the company which has a big NOSH and has a high risk to do a consolidation.

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------

BANYAK NEWS TANDANYA NEXGRAM ADA BANYAK BUSINESS SEKARANG.
NEXGRAM SEKARANG BUKAN NEXGRAM DULU.
SELESAI MASALAH YANG DIHADAPI, NEXGRAM BOOOOOOM. HE HE


dan lagi, selepas Bonus Share, MYEG Nosh akan jadi 8 bilion lebih. Bacalah announcement.

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------
Pi main jauh-jauh. Pergi jaga ASB....... Kata semalam jual Nexgram beli ASB.

Apa macam sekarang.... Mapoh. Terjerat???

KUALA LUMPUR: Nexgram Holdings Berhad wholly owned subsidiary Associate Partners Laboratories Sdn Bhd (APLab) or (APLSB) on 12 August 2021 and 13 August 2021 has secured two contracts amounted RM57 million for sales and distribution of the Covid-19 consumables in Malaysia.

Of the two contracts, one was the sales contract valued at RM36 million from the procurement agreement of the Covid-19 Antigen Nasal and Saliva Test kits between APLab with the Covid-19 screening test kit distributor Ottigo Sdn Bhd (Ottigo).

APLab on 13 August 2021 also bag a sales contract order from R Clinic amounted RM21 million for the Covid-19 Vaccine Efficacy Antibody Test kits.

Based on the 13 August 2021 announcement at Bursa Malaysia, APLab, a wholly owned subsidiary of Nexgram on 12 August 2021 entered into Master Procurement Agreement (MPA) with Ottigo Sdn Bhd to procure and distribute licensed Covid-19 test consumables using TracVirus Clinic System.

APLab is the authorised seller of Covid-19 screening test consumables namely the Covid-19 related critical-care medical items including RTK Antibody Test Kit, RTK Antigen Nasal Test Kit, RTK Antigen Saliva/Breath Test Kit, quantitative RT-PCR machines, reagents, Neutralising Antibody Test Kit, Al and similar Covid-19 screening test, Professional use Instant Test Kits, parts, systems and solutions. Other Medical Supplies including but not limited to 3-ply Masks, N95 Face Masks, KN95 Face Masks, Surgical Masks, Ventilators, Personal Protective Equipment, Medical Protective Glasses, Disposable Surgical Medical Gown, Sanitizer, Ventilator.

Ottigo is the appointed distributor of APLab, and shall solely procure and distribute all directly or indirectly licensed Covid-19 screening test consumables using Tracvirus Clinic System from APLab. All procurement of consumable materials shall be supplied by APLab and the right are granted to Ottigo to sell and distribution the products in Malaysia.

Ottigo undertake to procure and distribution on Covid-19 screening test solution, subject to force majeure and market condition beyond natural control, in particular Covid-19 solutions, from APLSB Tracvirus Clinic System within twenty four (24) months, whereas sales across APLab’s existing direct clients shall consolidate to the Distributor as the master distributor for ease of on-going business management.

Based on the reports, the term of the MPA shall be for a period of two (2) years and shall thereafter continue in effect on auto renewal on a yearly basis. The contracts is expected to contribute positively to the earnings of the Nexgram Group during the tenure of the agreements.

Source: https://klse.i3investor.com/blogs/mzm511/2021-08-14-story-h1569741320-NEXGRAM_bags_RM57_million_contract_for_distribution_of_the_Covid_19_con.jsp

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------
Pergi jaga ASB....... He He He

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------

CUT LOSS NAK BAGI KAMU BELI HARGA MURAH KE???
BUKANNYA NEXGRAM NAK BANGKRAP PUN.
ISU SETTLE, NAIKLAH HARGA DIA..

WHAT AN OPPORTUNIST........ HE HE


BEGINILAH OPPORTUNIST INI CARI MAKAN.
TIMBULKAN KETAKUTAN DEMI MENCAPAI HASRAT CARI MAKAN MELALUI TINDAKAN SPEKULATIF MEREKA.

Nexgram SHARES From UNDER 3 billions increase to 3.8 billions.....MYEG Baru 3.6 billions BOH...ITU MYEG boh!!! NOT CAP AYAM!!!!Means your share in this CAP AYAM KAPUTT is CAIR/DILUTED.....
----------------
Selepas Bonus Share, MYEG Nosh akan jadi 8 bilion lebih. Bacalah announcement.

@hlh1965. Ex-date 27/8/2021 means those who buy the share on 27/8/2021 will not get the right for the RI shares. Only the existing units of shares held up to 30/8/2021 or the units bought on 26/8/2021 will be given the right of the RI shares.

The unit of share bought on 26/8/2021 will be added in the investor's CDS account only on 30/8/2028. The right or OR on the basis of 1 right for every existing 1 share will be given for the shares held on the entitlement date,30 Aug 2021.

Ex-Date 27 Aug 2021
Entitlement date 30 Aug 2021

1. We can sell the shares after 30/8/2021, and that time we already entitled for the right.
2. Free warrants will be given only when we subscribe the RI shares.

***REMARKS: I hope our sifu can correct me if I was wrong.

assell is the RI is rm0.06 ?
-----
YES

@OKU_2020 a.k.a The Spammer MDP = AbdulLeman_2021 dengan multi ID
-----------------

BANYAK NEWS TANDANYA NEXGRAM ADA BANYAK BUSINESS SEKARANG.
NEXGRAM SEKARANG BUKAN NEXGRAM DULU.
SELESAI MASALAH YANG DIHADAPI, NEXGRAM BOOOOOOM. HE HE

@TwaHuat. Saya rasalah, kalau tengok macam mana Nexgram dapat peluang untuk jadi sistem rasmi kerajaan bagi TracAPM- SafeTravelPass itu hari setelah mungkin bersaing dengan sistem MYEG, saya rasa pihak yang kuat menyokong Nexgram mungkin bekas menteri tugas-tugas khas dari Bersatu yang menjaga APM.

Satu lagi menteri tersebut, Mohd Redzuan adalah orang Melaka. Jadi saya terfikir juga bagaimana plan projek besar di Melaka itu di buat di Melaka. Macam ada kaitan sahaja.

MASTER PROCUREMENT AGREEMENT ENTERED INTO BETWEEN ASSOCIATE PARTNERS LABORATORIES SDN BHD ("APLSB"), A WHOLLY OWNED SUB-SUBSIDIARY WITH RELIABLE HEALTHCARE SDN BHD ("RHSB") TO PROCURE AND DISTRIBUTE APPROVED COVID-19 VACCINE EFFICACY ANTIBODY AND SALIVA ANTIGEN TEST KITS

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3183688..

MASTER PROCUREMENT AGREEMENT ENTERED INTO BETWEEN ASSOCIATE PARTNERS LABORATORIES SDN BHD ("APLSB"), A WHOLLY OWNED SUB-SUBSIDIARY WITH RELIABLE HEALTHCARE SDN BHD ("RHSB") TO PROCURE AND DISTRIBUTE APPROVED COVID-19 VACCINE EFFICACY ANTIBODY AND SALIVA ANTIGEN TEST KITS

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3183688

Waiting for a good announcement from Kanger, BEFORE THE EX-DATE OR AT LEAST BEFORE THE ACCEPTANCE AND PAYMENT DATE.

If there is any, its can be a catalyst for the price to be pushed up. The current price later should be push up to the higher level to make sure that the RI will be a success.

Take a note that the issue price for the RI share is @ 6 sen per share.>>>>>>>>>>>>>>>>>

@wistlebower99.

I'm afraid if you're one of the spammers who could gain much by spamming certain counter and speculating on the counter for your own sake.

I’m asking you a question. Are you holding any Kanger shares?????

SOME RELATED NOTES:

Earlier this year, Sinopharm entered into a joint venture with UAE-based G42 to produce the Sinopharm Covid-19 vaccines in the country under the Hayat-Vax brand.

The made-in-UAE vaccine was the first Covid-19 vaccine to be produced in the Arab world.

"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.

Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.



MY CONCLUSION:

If the approval of the Hayat-Vax Sinopharm Covid-19 vaccine with NPRA can be done by August 2021, it’s a very good prospect for Kanger to realize its plan to execute their Covid-19 vaccine distributorship in Malaysia.

Source: https://klse.i3investor.com/blogs/mzm511/2021-08-17-story-h1569797152-What_Happened_to_Kanger_s_Plan_To_Distribute_Hayat_Vax_Covid_19_Vaccine.jsp

mo1malaysia You typed "2" twice...
---------------
Typo. He He


-------------------
..... I also can plan, anyone also can plan.. But can execute or not? Glove mana?

Betul. Sebaik mana pun syarikat, kadang-kadang dalam banyak plan yang dibuat, bukan semuanya berjaya. Boleh jalan dan dilaksanakan. Tapi untuk Kanger sekarang beberapa plan sudah berjaya dan sebahagiannya dalam proses:

1. Sudah berjaya dalam kontrak bernilai RM478 juta bagi projek pembinaan di Genting Highland.
2. Dalam proses terakhir untuk pengambil alihan sebahagian kepentingan dalam syarikat Sung Master yang terlibat dalam pembekalan bahan binaan.
3. Kita sedang menanti progress untuk plan pembekalan vaksin Hayat Vax. Sama ada berjaya atau tidak. Buat masa ini, tidak adil untuk kita katakan bahawa plan tersebut telah gagal.


Logik saya, kalau sebuah syarikat langsung tak ada plan untuk mengatasi masalah dalam syarikat atau untuk meningkatkan lagi perniagaan syarikat, akan adakah peluang perniagaan yang datang sendiri???? Memang susah mahu dapat peluang kan.

Oleh itu, mesti ada plan. Tanpa plan memang peluang adalah ZERO..

Kalau senang boleh rujuk: https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-The_Currents_Status_of_MOUs_and_Agreements_Relating_To_KANGER_0170.jsp

@whistlebower99.

For your information the NOSH of Hong Seng also quite high. It's at 2,457 Million.
To add, MyEG also will record the NOSH at 8+ bil when the company completed its Bonus Share exercises.

Please do not compare certain company with different management and different problem with ALMOST ALL the companies in FINTECH group... Please don't ever be A BLIND PARROT spammer anymore. I BEG YOU.

By the way, I also hope you can put Hong Seng and MyEG in your list of the company which has a big NOSH and has a high risk to do a consolidation.

@wistlebower99.

SOME ADVICE FOR YOU:
1. Please don't give any conclusion about a company without knowing any basic knowledge of accounting or finance.

2. Some of the information or assumptions given was not true or misleading. Please do research for the true information.

32. Please don’t ever think that a company without any plans to do business is better than a
company which has a plan to do businesses.

What kind of THE BLIND PARROT company analyst you are. The cheap plug spammer. Haish

MY ACCUSATION ON YOU:
1. Infact, I suspect you have an ulterior motive.

2. Your analysis on certain companies looked bias, untrue and misleading. It's not fair to the company and its current shareholders.

3. I'm afraid if you're one of the spammers who could gain much by spamming certain counter and speculating on the counter for your own sake.

I’m asking you a question. Are you holding any Nexgram shares?????

@wistlebower99.

SOME ADVICE FOR YOU:
1. Please don't give any conclusion about a company without knowing any basic knowledge of accounting or finance.

2. Some of the information or assumptions given was not true or misleading. Please do research for the true information.

2. Please don’t ever think that a company without any plans to do business is better than a
company which has a plan to do businesses.

What kind of THE BLIND PARROT company analyst you are. The cheap plug spammer. Haish

MY ACCUSATION ON YOU:
1. Infact, I suspect you have an ulterior motive.

2. Your analysis on certain companies looked bias, untrue and misleading. It's not fair to the company and its current shareholders.

3. I'm afraid if you're one of the spammers who could gain much by spamming certain counter and speculating on the counter for your own sake.

I’m asking you a question. Are you holding any Kanger shares?????

hlh1962 @MZM Tks for all the informations. Newbie in share investment and first time subscription of right issues. May I know how to make payment for the right issues? 2) when is the last date to make payment?
-----------------
Later, we can follow the instruction given by the company on how to subscribe and make payments - which will be included in the incoming company's circular /announcement.

And ..... The last date of acceptance and Payment 15 Sep 2021 05:00 PM

Waiting for a good announcement from Kanger, BEFORE THE EX-DATE OR AT LEAST BEFORE THE ACCEPTANCE AND PAYMENT DATE.

If there is any, its can be a catalyst for the price to be pushed up. The current price later should be push up to the higher level to make sure that the RI will be a success.

Take a note that the issue price for the RI share is @ 6 sen per share.>>>>>>>>>>>>>>>>>

Peace99 MZM, thanks for the prompt alert!
Wonder any info on online subscription of rights?
----------------
Have to wait for another announcement.

Tarikh-tarikh pelaksanaan RI untuk Kanger:

Ex-Date 27 Aug 2021
Entitlement date 30 Aug 2021 Despatch Date 02 Sep 2021
Date for commencement of trading of rights 01 Sep 2021
Date for cessation of trading of rights 08 Sep 2021
Date for announcement of final subscription result and basis of allotment of excess Rights Securities 23 Sep 2021
Last date and time for :
Sale of provisional allotment of rights 07 Sep 2021 05:00 PM
Transfer of provisional allotment of rights 09 Sep 2021 04:30 PM
Acceptance and Payment 15 Sep 2021 05:00 PM
Excess share application and payment 15 Sep 2021 05:00 PM
Available/Listing Date 30 Sep 2021 Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3183477

Yes. We will given the warrant at no cost, but have to pay the cost for right issue share subscribed. 6 sen for one RI share.

rr1688.
The quantity of the Hayat Vax vaccine is 5 mil doses + Additional 5 mil doses. If Kanger can get it, I think it's already a sufficient quantity.

rr1688.
Based on the agreement, Kanger only can distribute the Hayat Vax in Malaysia. It's not for reexport to other countries..

@hlh1962.
1. Does it mean that for every kanger right issue at rm60.00 @0.06
Answer: One free warrant will be given to one right issue share subscribed @ 6 sen per share.

2. .... we subscribe we can get free warrant worth rm50.00 @0.05?
Answer: It doesn't mean like that. The free warrant's price will be determined in the market when it listed. RM0.05 is the exercise price set for converting one warrant into one ordinary share.

We can convert a warrant + payment of 5 sen to get one ordinary share. We can hold the warrant or convert it into share or sell it in the market at their current price.

3. Normally how long we can sell the warrants and the right issue shares?
Answer: From the first day the warrant and right issue shares listed and traded in the market.

We refer to the earlier announcements dated 24 February 2021, 19 April 2021, 26 April 2021 and 2 June 2021 in relation to the Proposals.

On behalf of the Board, UOB Kay Hian wishes to announce that the Board had on 16 August 2021 ("Price-Fixing Date") resolved to fix the exercise price of the Warrants B at RM0.05 per Warrant B ("Exercise Price").

The Exercise Price was determined and fixed by the Board after taking into consideration, amongst others, the following:-

i. The Warrants B will be issued at no cost to the Entitled Shareholders and/ or their renouncee(s) and/ or transferee(s) who successfully subscribe for the Rights Shares;

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3183247

@OKU_2020 a.k.a The Spammer Dog dengan multi ID
--------------------
Apa awak kesah. Sesen pun wa tak minta duit awak nak beli saham.
Duduk suruh orang cut loss buat APA? Nak banyak buat pahala ye.
Ini mesti lebai besar ni. He He

@OKU_2020 a.k.a The Spammer Dog dengan multi ID sedang buat kacau...

Tengok saja apa yang berlaku esok. SEMUA BOLEH JADI

@whistlebower99. And please don't ever be as lower than OKU_2020 a.k.a The Spammer Dog standard.
Even if you want to be a spammer or naysayer, please uplift your standard. Please make it more higher than his/hers.

@whistlebower99.

I'm eagerly waiting for the 4QR 2021 report. A very crucial report card from Nexgram I'm waiting for.

A sales contract should be served as a contract. It's not merely a MOU or unbounded agreement.

I studied Hong Seng with its several contracts awarded related to Covid-19 test kits. And the share price of Hong Seng shoot up from RM0.75 up to RM1.64. For your information the NOSH of Hong Seng also quite high. It's at 2,457 Million.

Please do not compare certain company with different management and different problem with ALMOST ALL the companies in FINTECH group... Please don't ever be A BLIND PARROT spammer anymore. I BEG YOU.

By the way, I also hope you can put Hong Seng in your list of the company which has a big NOSH and has a high risk to do a consolidation.

NEXGRAM bags RM57 million contract for distribution of the Covid-19 consumables

KUALA LUMPUR: Nexgram Holdings Berhad wholly owned subsidiary Associate Partners Laboratories Sdn Bhd (APLab) or (APLSB) on 12 August 2021 and 13 August 2021 has secured two contracts amounted RM57 million contract for sales and distribution of the Covid-19 consumables in Malaysia.

Of the two contracts, one was valued at RM36 million from the procurement agreement of the Covid-19 Antigen Nasal and Saliva Test kits between APLab with the Covid-19 screening test kit distributor Ottigo Sdn Bhd (Ottigo).

APLab on 13 August 2021 also bag a sales contracts order from R Clinic amounted RM21 million for the Covid-19 Vaccine Efficacy Antibody Test kits.

Based on the 13 August 2021 announcement at Bursa Malaysia, APLab, a wholly owned subsidiary of Nexgram on 12 August 2021 entered into Master Procurement Agreement with Ottigo Sdn Bhd to procure and distribute licensed Covid-19 test consumables using TracVirus Clinic System.

APLab is the authorised seller of Covid-19 screening test consumables namely the Covid-19 related critical-care medical items including RTK Antibody Test Kit, RTK Antigen Nasal Test Kit, RTK Antigen Saliva/Breath Test Kit, quantitative RT-PCR machines, reagents, Neutralising Antibody Test Kit, Al and similar Covid-19 screening test, Professional use Instant Test Kits, parts, systems and solutions. Other Medical Supplies including but not limited to 3-ply Masks, N95 Face Masks, KN95 Face Masks, Surgical Masks, Ventilators, Personal Protective Equipment, Medical Protective Glasses, Disposable Surgical Medical Gown, Sanitizer, Ventilator.

Ottigo is the appointed distributor of APLab, and shall solely procure and distribute all directly or indirectly licensed Covid-19 screening test consumables using Tracvirus Clinic System from APLab. All procurement of consumable materials shall be supplied by APLab and the right are granted to Ottigo to sell and distribution the products in Malaysia.

Ottigo undertake to procure and distribution on Covid-19 screening test solution, subject to force majeure and market condition beyond natural control, in particular Covid-19 solutions, from APLSB Tracvirus Clinic System within twenty four (24) months, whereas sales across APLab’s existing direct clients shall consolidate to the Distributor as the master distributor for ease of on-going business management.

Based on the reports, the term of the MPA shall be for a period of two (2) years and shall thereafter continue in effect on auto renewal on a yearly basis. The contracts is expected to contribute positively to the earnings of the Nexgram Group during the tenure of the agreements.

Source: https://klse.i3investor.com/blogs/mzm511/2021-08-14-story-h1569741320-NEXGRAM_bags_RM57_million_contract_for_distribution_of_the_Covid_19_con.jsp